SHR-7787 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-7787, a DLL3-targeted bispecific T-cell engager, in relapsed small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC): results from a phase 1/2 trial (ESMO 2026) - No abstract available

Bispecific • P1/2 data • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SHR-7787-101: A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=201 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial primary completion date • Oncology • Solid Tumor

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

New P2 trial • Oncology • Solid Tumor

Hengrui Pharma (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd., have received the ’Clinical Trial Approval Notice’ (FUTU) - "...issued by the National Medical Products Administration for SHR-7787 Injection, SHR-4849 Injection, Bevacizumab Injection, and Adebrelimab Injection."

New trial • Solid Tumor

SHR-7787-101: A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=201 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=201 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor

Hengrui Medicine: Clinical trials of its subsidiary drugs SHR-3821 injection and SHR-7787 injection were approved [Google translation] (163.com) - "On August 9, Hengrui Medicine (600276) issued an announcement...that its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biopharmaceutical Co., Ltd. received the 'Drug Clinical Trial Approval Notice' for SHR-3821 Injection and SHR-7787 Injection approved by the National Medical Products Administration, and clinical trials will be carried out in the near future. SHR-3821 injection is a humanized antibody drug independently developed by the company. It is intended to be used to treat advanced malignant solid tumors...SHR-7787 injection is a Class 1 therapeutic biological product that induces and activates T cells to enable them to play a role in targeted killing of malignant solid tumor cells."

New trial • Hematological Malignancies • Oncology • Solid Tumor